GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (LTS:0RC7) » Definitions » Short Percentage of Float

Hansa Biopharma AB (LTS:0RC7) Short Percentage of Float


View and export this data going back to 2015. Start your Free Trial

What is Hansa Biopharma AB Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Hansa Biopharma AB's Short Percentage of Float

For the Biotechnology subindustry, Hansa Biopharma AB's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hansa Biopharma AB's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's Short Percentage of Float falls into.


;
;

Hansa Biopharma AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (LTS:0RC7) » Definitions » Short Percentage of Float
Comparable Companies
OSTO:BINV OSTO:VICO OSTO:GENO OSTO:EGTX OSTO:XSPRAY OSTO:SANION OSTO:SYNACT OSTO:DMYD B XSAT:HAMLET B OSTO:IBT B VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
HNSA:Sweden 24H:Germany
Address
Scheelevagen 22, Lund, SWE, 223 63
Website
https://www.hansabiopharma.com
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB Headlines

No Headlines